In:
International Journal of Cancer, Wiley, Vol. 136, No. 5 ( 2015-03)
Abstract:
What's new? While ABT‐737 exhibits apoptotic activity as a single agent in a wide variety of cancer cells, in ovarian cancers Mcl‐1 expression seemingly has to be down‐regulated for ABT‐737 to be effective. Here, using fresh patient ovarian tumor samples, the authors assessed the sensitivity of tumor nodes to ABT‐737 combined with carboplatin, an indirect inhibitor of Mcl‐1. ABT‐737 showed promise as a monotherapy, with Bim acting as a robust predictive response factor. Bim's predictive value was strongly improved by the concomitant consideration of P–Erk and Mcl‐1 expression levels, which provides an attractive strategy for the selection of patients in clinical trials.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
